2-(3-chlorophenyl)ethane-1-thiol | 1267263-12-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-chlorophenyl)ethane-1-thiol
• 英文别名: 2-(3-chlorophenyl)ethanethiol
• CAS: 1267263-12-6
• 化学式: C₈H₉ClS
• mdl: MFCD11521139
• 分子量: 172.678
• InChiKey: VZNQYQKVSCPFHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(3-chlorophenyl)ethane-1-thiol 、 8-氯-3,7-二氢-1,3,7-三甲基-1H-嘌呤-2,6-二酮 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 8-[2-(3-Chlorophenyl)ethylsulfanyl]-1,3,7-trimethylpurine-2,6-dione
  参考文献：
  名称：

  Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues

  摘要：

  In a previous study we have investigated the monoamine oxidase (MAO) inhibitory properties of a series of 8-sulfanylcaffeine analogues. Among the compounds studied, 8-[(phenylethyl) sulfanyl] caffeine (IC50 = 0.223 mu M) was found to be a particularly potent inhibitor of the type B MAO isoform. In an attempt to discover potent MAO inhibitors and to further examine the structure-activity relationships (SAR) of MAO inhibition by 8-sulfanylcaffeine analogues, in the present study a series of 8-[(phenylethyl)sulfanyl] caffeine analogues were synthesized and evaluated as inhibitors of human MAO-A and -B. The results document that substitution on C3 and C4 of the phenyl ring with alkyl groups and halogens yields 8-[( phenylethyl) sulfanyl] caffeine analogues which are potent and selective MAO-B inhibitors with IC50 values ranging from 0.017 to 0.125 mu M. The MAO inhibitory properties of a series of 8-sulfinylcaffeine analogues were also examined. The results show that, compared to the corresponding 8-sulfanylcaffeine analogues, the 8-sulfinylcaffeins are weaker MAO-B inhibitors. Both the 8-sulfanylcaffeine and 8-sulfinylcaffeine analogues were found to be weak MAO-A inhibitors. This study also reports the MAO inhibition properties of selected 8-[(phenylpropyl) sulfanyl] caffeine analogues. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.10.005
• 作为产物：
  描述：

  3-氯苯乙基溴 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 2-(3-chlorophenyl)ethane-1-thiol
  参考文献：
  名称：

  Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues

  摘要：

  In a previous study we have investigated the monoamine oxidase (MAO) inhibitory properties of a series of 8-sulfanylcaffeine analogues. Among the compounds studied, 8-[(phenylethyl) sulfanyl] caffeine (IC50 = 0.223 mu M) was found to be a particularly potent inhibitor of the type B MAO isoform. In an attempt to discover potent MAO inhibitors and to further examine the structure-activity relationships (SAR) of MAO inhibition by 8-sulfanylcaffeine analogues, in the present study a series of 8-[(phenylethyl)sulfanyl] caffeine analogues were synthesized and evaluated as inhibitors of human MAO-A and -B. The results document that substitution on C3 and C4 of the phenyl ring with alkyl groups and halogens yields 8-[( phenylethyl) sulfanyl] caffeine analogues which are potent and selective MAO-B inhibitors with IC50 values ranging from 0.017 to 0.125 mu M. The MAO inhibitory properties of a series of 8-sulfinylcaffeine analogues were also examined. The results show that, compared to the corresponding 8-sulfanylcaffeine analogues, the 8-sulfinylcaffeins are weaker MAO-B inhibitors. Both the 8-sulfanylcaffeine and 8-sulfinylcaffeine analogues were found to be weak MAO-A inhibitors. This study also reports the MAO inhibition properties of selected 8-[(phenylpropyl) sulfanyl] caffeine analogues. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.10.005

文献信息

• [EN] ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS<br/>[FR] INHIBITEURS ALPHA-D-GALACTOSIDE DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2016120403A1

  公开（公告）日：2016-08-04

  The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns compounds for use in a method of treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

  本发明涉及一般式（1）的化合物。其中吡喃糖环为α-D-半乳糖，A选自。该式（1）化合物适用于治疗与在哺乳动物，如人类中的一个配体结合相关的疾病的方法。此外，本发明涉及用于治疗与在哺乳动物，如人类中的一个配体结合相关的疾病的方法的化合物。
• Azetidine derivatives, their preparation and medicaments containing them
  申请人：——

  公开号：US20020035102A1

  公开（公告）日：2002-03-21

  The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R 1 is methyl or ethyl; R 2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R 3 and R 4 , identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them. 1

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。
• Acetindine derivatives, their preparation and medicaments containing them
  申请人：——

  公开号：US20030162808A1

  公开（公告）日：2003-08-28

  Disclosed are azetidine derivatives of formula: 1 their optical isomers, their salts, their preparation and medicaments containing them.

  本发明涉及一种公开的式（1）的氮杂环丙烷衍生物，其光学异构体，其盐，其制备方法以及含有它们的药物。
• AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
  申请人：Achard Daniel

  公开号：US20060270649A1

  公开（公告）日：2006-11-30

  Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.

  本发明涉及一种式子为的氮杂环丙烷衍生物，包括其光学异构体、其盐、其制备方法以及含有它们的药物。
• PYRIMIDINE DERIVATIVE, PRODUCTION THEREOF, AND ANDROGEN INHIBITOR
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0503099A1

  公开（公告）日：1992-09-16

  A pyrimidine derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, and an androgen inhibitor comprising the same having an excellent effect of treating prostatic hyperplasia, female hypertrichosis, and male baldness or pimple: wherein R¹ represents hydrogen or hydroxyl; R² represents hydrogen, lower alkoxycarbonyl, lower alkoxy, halogen, lower alkyl, C₃ to C₈ cycloalkyl, lower alkoxycarbonyl lower alkyl, carboxyl, carboxylated lower alkyl, CONHR, cyano, phenyl, phenylated lower alkyl, lower alkanoyloxy lower alkyl, benzoyl, lower alkanoyl or hydroxylated lower alkyl; R³ represents hydrogen, hydroxy, lower alkyl, C₃ to C₈ cycloalkyl, halogenated lower alkyl or phenyl; R⁴ represents hydrogen, lower alkyl or lower alkoxy, R⁵ represents hydrogen, lower alkyl, lower alkoxy lower alkyl or halogenated lower alkyl.

  一种由通式(I)代表的嘧啶衍生物、其药学上可接受的盐，以及由其组成的雄激素抑制剂，具有治疗前列腺增生、女性多毛症、男性秃头或丘疹的良好效果：其中，R¹代表氢或羟基；R²代表氢、低级烷氧基羰基、低级烷氧基、卤素、低级烷基、C₃至C₈环烷基、低级烷氧基羰基低级烷基、羧基、羧化低级烷基、CONHR、氰基、苯基、苯基化低级烷基、低级烷酰氧基低级烷基、苯甲酰基、低级烷酰基或羟化低级烷基；R³ 代表氢、羟基、低级烷基、C₃至 C₈ 环烷基、卤代低级烷基或苯基；R⁴ 代表氢、低级烷基或低级烷氧基，R⁵ 代表氢、低级烷基、低级烷氧基低级烷基或卤代低级烷基。